Kyowa Hakko Kirin Co., Limited

Masamori Sugawara

Noriaki Uesaka

Yoshisuke Nakasato

Takao Nakajima

Yuji Nomoto

Tetsuji Ohno

Shin-ichi Uchida

Takashi Sawada

Takayuki Furuta

Yushi Kitamura

Tomohiro Danjo

Naoto Osakada

Satoshi Kaneko

Atsuko Mizutani

Keishi Katayama

Keiichi Motosawa

Maki Ichioka

Mariko Osakada

Shin-Ichi Uchida

A ring-fused heterocyclic derivative represented by the following general formula (I) or a pharmaceutically acceptable salt thereof having a T-type calcium channel regulatory effect and useful as a pruritus therapeutic and/or preventive agent, and the like are provided. In the general formula (I), Rrepresents optionally substituted lower alkyl, and the like; Rrepresents an optionally substituted cycloalkyl, and the like; Q represents a hydrogen atom, and the like; Rrepresents &#x2014;C(&#x2550;O)NRR(wherein Rand Rmay be the same or different, and each represents a hydrogen atom, and the like), and the like; Lrepresents &#x2014;CRR&#x2014; (wherein Rand Rmay be the same or different, and each represents a hydrogen atom, and the like), and the like; and Wand Wmay be the same or different, and each represents C&#x2014;R(wherein Rrepresents a hydrogen atom, and the like), and the like. 

Ring-fused heterocyclic derivative

Method of treating central nervous systems disease by administering wherein n is an integer of from 0 to 3; Ris a 5-membered aromatic heterocyclic group containing at least one oxygen atom; Ris &#x2014;COR(wherein Ris aryl); Ris hydrogen or lower alkyl; and Rrepresents cycloalkyl, aryl, aralkyl, alicyclic heterocyclic group, aromatic heterocyclic group, alicyclic hetocyclic-alkyl, or aromatic heterocyclic-alkyl, and R, R, Rand Rare individually optionally substituted.

Thiazole derivatives

Wherein n is an integer of from 0 to 3; Ris a 5-membered aromatic heterocyclic group containing at least one oxygen atom; Ris &#x2014;COR(wherein Ris aryl); Ris hydrogen or lower alkyl; and Rrepresents cycloalkyl, aryl, aralkyl, alicyclic heterocyclic group, aromatic heterocyclic group, alicyclic hetocyclic-alkyl, or aromatic heterocyclic-alkyl, and R, R, Rand Rare individually optionally substituted. 

A CB2 receptor modulator comprising an imidazole derivative represented by the general formula (I): [wherein, Rrepresents optionally substituted lower alkyl or the like; Rrepresents optionally substituted cycloalkyl or the like; Rrepresents optionally substituted aryl or the like; and n represents an integer of 0 to 3] or a pharmaceutically acceptable salt thereof as an active ingredient, and the like are provided.

Imidazole derivatives

(Wherein n is an integer of from 0 to 3; Ris substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic group; Ris halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, &#x2014;COR, or the like; Rand Rmay be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, &#x2014;COR, or the like) For example, provided are adenosine Areceptor antagonists comprising, as the active ingredient, a thiazole derivative represented by a general formula (I), or a pharmaceutically acceptable salt thereof, and the like. 

Growing community of inventors

Mishima, Japan

Masamori Sugawara